Cambridge-based Moderna Working With Swiss Company To Make COVID-19 Vaccine

CAMBRIDGE, Mass. (WBZ NewsRadio) — Cambridge biotech Moderna announced Friday they would be working with a company in Switzerland in their continuing development of a vaccine for COVID-19.

Manufacturing suites for the potential vaccine are set to be established at Swiss company Lonza’s facilities in both the United States and in Switzerland. This is intended to develop up to a billion doses of the vaccine.

The first batches of the vaccine are set to be developed at Lonza in July, with the technology being transferred to them next month.

“We are very pleased to partner with Lonza, which shares our commitment to rapidly addressing this pandemic which has created a global health crisis,” Stéphane Bancel, Moderna’s Chief Executive Officer, said in a statement.

Moderna began working on the vaccine at the beginning of this year, with the first clinical batch completed in February.

Follow WBZ NewsRadio: Facebook | Twitter | Instagram | iHeartmedia App

(Photo: Getty Images)

Sponsored Content

Sponsored Content